Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(21 sites)
Japan
Nagoya Heart Center, Nagoya, Aichi-ken Toyohashi Heart Center, Toyohashi, Aichi-ken New Tokyo Hospital, Matsudo, Chiba Kokura Kinen Hospital, Kitakyushu, Fukuoka Gifu Heart Center, Gifu, Gifu Medical Corporation Sapporo Heart Center Sapporo Cardio Vascular Clinic, Sapporo, Hokkaido Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido Tokai University Hospital, Isehara, Kanagawa St.Marianna University Hospital, Kawasaki, Kanagawa Sendai Kousei Hospital, Sendai, Miyagi Kurashiki Central Hospital, Kurashiki, Okayama-ken The Sakakibara Heart Institute of Okayama, Okayama, Okayama-ken Kindai University Hospital, Ōsaka-sayama, Osaka Juntendo University Hospital, Bunkyo-ku, Tokyo Mitsui Memorial Hospital, Chiyoda-ku, Tokyo Sakakibara Heart Institute, Fuchū, Tokyo Teikyo University Hospital, Itabashi-ku, Tokyo IMS Tokyo Katsushika General Hospital, Katsushika-ku, Tokyo Toho University Omori Medical Center, Ōta-ku, Tokyo Keio University Hospital, Shinjuku-ku, Tokyo Toyama University Hospital, Toyama, Toyama